REGN News and Press, Regeneron Pharmaceuticals Inc. From 06/06/24

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...

A look at the top 10 most actives in the United States ENDRA Life Sciences Inc. (NDRA) rose 63.4% to $0.1389 on volume of 479,696,316 shares Nuvve Holding Corp. (NVVE) rose 53.3% to $0.868 on volume of 157,337,871 shares PROSHARES TRUST (SQQQ) fell 6.1% to $9.26 on volume of 149,796,858 s...

2024-06-05 12:43:09 ET Regeneron Pharmaceuticals, Inc. (REGN) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ET Company Participants Mark Hudson - Investor Relations Israel Lowy - SVP of Translational & Clinical Sciences, Oncology Andres Sir...

2024-06-04 11:30:03 ET Truist Financial analyst issues UNDERPERFORM recommendation for REGN on June 4, 2024 10:01AM ET. The previous analyst recommendation was Underperform. REGN was trading at $995.93 at issue of the analyst recommendation. The overall analyst consensus...

2024-06-03 17:38:01 ET More on FibroGen Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript FibroGen falls after early-stage data for prostate cancer drug Seeking Alpha’...

A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 17.9% to $0.1179 on volume of 290,472,504 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 7.1% to $0.6248 on volume of 223,394,331 shares GameStop Corporation (GME) rose 21.0% to $28...

2024-06-03 15:00:06 ET Evan David Seigerman from BMO Capital issued a price target of $1,082.00 for REGN on 2024-06-03 12:28:00. The adjusted price target was set to $1,082.00. At the time of the announcement, REGN was trading at $992.4728. The overall price target conse...

2024-06-02 14:00:00 ET PD-1/PD-L1 inhibitors, some of the most commonly used cancer therapies, achieved $52B in spending worldwide in 2023, a number expected to reach $90B in 2028. Examples include Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), Bristol Myers Squibb's ( NYSE: BM...

2024-05-31 06:49:06 ET More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Regeneron Pharmaceuticals, Inc. (REGN) Q1...

2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...